Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.
de Lima, Loyze Paola O; Seabra, Sergio H; Carneiro, Henrique; Barbosa, Helene S.
Antimicrob Agents Chemother
; 59(9): 5239-49, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26077255
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.
Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis.
Within-host selection of drug resistance in a mouse model of repeated interrupted treatment of Plasmodium yoelii infection.
In Vitro Analysis of the Interaction between Atovaquone and Proguanil against Liver Stage Malaria Parasites.
Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Within-Host Selection of Drug Resistance in a Mouse Model Reveals Dose-Dependent Selection of Atovaquone Resistance Mutations.
New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis.
3-Bromopyruvate as a potential pharmaceutical in the light of experimental data.
Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.